

**Amendments to the Claims:**

- 1-38. (canceled)
39. (canceled)
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (currently amended) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide shown in Figure 17 (SEQ ID NO: 39);
  - (b) ~~the amino acid~~ amino acid sequence of the polypeptide shown in Figure 17 (SEQ ID NO: 39), lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209396.
45. (previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 17 (SEQ ID NO:39).
46. (previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 17 (SEQ ID NO:39), lacking its associated signal peptide.
- 47-48. (canceled)
49. (previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209396.

50. (currently amended) A chimeric polypeptide comprising a polypeptide according to Claim ~~39~~ 44 fused to a heterologous polypeptide.

51. (previously presented) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.